JGJuan Carlos López Gutiérrez

Juan Carlos López Gutiérrez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Carlos López Gutiérrez has a total of 225 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of Malignant Peripheral Nerve Sheath Tumor subtypes with distinct genomic identities

    by Miriam Magallón-Lorenz, Juana Fernández-Rodríguez, Helena Mazuelas, Itziar Uriarte-Arrazola, Sara Ortega-Bertrán, Edgar Creus-Bachiller, Judit Farrés-Casas, Aleix Mendez, Eva Rodríguez, Mariona Suñol, et al.

    Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas arising sporadically or in people with neurofibromatosis type 1 (NF1). Their marked heterogeneity challenges diagnosis and has hampered an integrative view of MPNST molecular pathogenesis. Here, a thorough whole-genome and transcriptome analysis of MPNSTs and the re-analysis of a large independent cohort allowed us to identify three molecular subtypes of MPNSTs (G1-G3) with distinct genomic identities and clinicopathological features. Furthermore, it provided a simple and unifying model of MPNST development, defining a distinct progression path for each group. This work uncovers new genomic aspects of MPNSTs, including the identification of recurrent copy-neutral loss of heterozygosity regions, distinct copy-number profiles among G1-G3, and CDKN2A -inactivating translocations in pre-malignant lesions (ANNUBPs). Altogether, these analyses overcome the dominant influence of PRC2 status in MPNST classification and provide a framework for their differential diagnosis and potential precision oncology treatment. SIGNIFICANCE: MPNST is a highly heterogeneous soft-tissue sarcoma with difficult clinical management and no effective systemic therapies. This work defines three molecular subtypes of MPNSTs with distinct development paths and histological and clinical characteristics with potential impact on translational studies and subtype-tailored treatments.


  • Open Access

    Clinical Applications of Indocyanine Green Fluorescence Imaging in Vascular Malformations: A Systematic Review

    by Carlos Delgado-Miguel, Javier Arredondo-Montero, Julio César Moreno-Alfonso, Marta Rodríguez Ruiz, Isabella Garavis Montagut, Paloma Triana Junco, Miriam Miguel-Ferrero, Mercedes Díaz, Francisco Hernández-Oliveros, Juan Carlos López-Gutiérrez

    Background/Objectives: The use of near-infrared fluorescence (NIRF) imaging with indocyanine green (ICG) has gained increasing attention in the management of vascular malformations, offering real-time visualization of vascular and lymphatic structures that may improve surgical precision and outcomes. Methods: A systematic review was conducted in accordance with PRISMA guidelines, searching PubMed, Web of Science, CINAHL, and EMBASE databases for studies evaluating the intraoperative use of ICG in vascular malformations, which was prospectively registered in PROSPERO (CRD420251131951). Two independent reviewers screened all records based on predefined eligibility criteria. Extracted data included study design, patient characteristics, ICG administration protocols, clinical applications, and perioperative outcomes. Results: A total of 33 studies comprising 433 patients treated between 2014 and 2025 were included for qualitative synthesis. Nineteen (57.6%) were case reports, seven (21.2%) retrospective descriptive studies, two (6.1%) retrospective comparative studies, three (9.1%) prospective comparative trials, and two (6.1%) prospective descriptive studies. Clinical indications for ICG included capillary and venous malformations (5 studies), arteriovenous malformations (9 studies), and lymphatic malformations (19 studies). Quality assessment with the MINORS tool showed that most studies scored < 17, while only seven reached 18–24, reflecting higher methodological quality. Conclusions: Intraoperative ICG fluorescence imaging represents a promising adjunct in the treatment of vascular malformations, providing real-time visualization that may facilitate lesion delineation, guide resection, and support minimally invasive techniques such as lymphaticovenous anastomosis. However, current evidence is largely descriptive, with very limited comparative outcome data, and high-quality studies are needed to determine whether these technical advantages translate into improved long-term clinical outcomes.


  • Open Access

    Use of Integra® Dermal Regeneration Template Bilayer in Burn Reconstruction: Narrative Review, Expert Opinion, Tips and Tricks

    by Clemens Maria Schiestl, Naiem Moiemen, Patrick Duhamel, Isabel Jones, Marcello Zamparelli, Juan Carlos López-Gutiérrez, Simon Kuepper

    Burn injuries remain a complex clinical challenge, particularly in reconstructive settings where donor sites are limited. Integra® Dermal Regeneration Template (IDRT), a bilayer dermal substitute, facilitates neodermis formation and supports functional and aesthetic recovery following burn trauma. This narrative review and expert opinion synthesizes current literature and clinical experience on the application of IDRT in post-burn reconstruction. It discusses the biological mechanism of dermal regeneration, surgical protocols including wound bed preparation and grafting, and considerations for anatomical regions such as the face, torso, and limbs. The review emphasizes key factors influencing successful outcomes, including patient selection, timing, and multidisciplinary coordination. Potential complications, such as infection, hematoma, and poor graft adherence, are addressed along with prevention and management strategies. Special considerations for pediatric and elderly populations are also highlighted. Through evidence-based insights and illustrative case examples, this review aims to inform surgical decision-making and promote best practices in reconstructive burn care using IDRT.


  • Open Access

    Non-Involuting Congenital Hepatic Hemangioma: Lessons from a Case Series

    by Karla Estefanía-Fernández, Paloma Triana, Carla Ramírez-Amorós, Mireia Gaspar-Pérez, Antonio Jesús Muñoz-Serrano, María Velayos, María San Basilio, Nelson M. Buitrago, Manuel Parrón, Ane Andrés, et al.

    Background: Congenital hepatic hemangiomas (CHHs) are typically considered rapidly involuting tumors, similar to their cutaneous counterparts (RICHs). However, non-involuting tumors remain poorly characterized. This study examines the evolutionary patterns and management strategies for non-involuting congenital hepatic hemangiomas (NICHHs). Methods: We conducted a retrospective review of clinical, imaging, histological, and genetic data of children diagnosed with NICHH—defined as showing no signs of involution for at least 18 months—between 1991 and 2022. Results: Seven patients (five females, two males) were identified. The median age at diagnosis was 42 days (range: 0–1440). Five patients had asymptomatic lesions, predominantly located in the right hepatic lobe. Histologic confirmation was available in three cases, and a GNAQ gene mutation was identified in one. The median follow-up period was 75 months (range: 35–191). Three patients with giant NICHH were treated with sirolimus, resulting in partial response in two cases and lesion stabilization in one. The four untreated patients showed diverse evolutionary patterns, including delayed involution and tardive growth. Conclusions: NICHH lesions demonstrate distinct long-term evolution. Accurate diagnosis and regular monitoring are essential to avoid unnecessary interventions. Sirolimus may offer a promising non-surgical treatment for select patients, particularly those with giant lesions.


  • Open Access

    [Translated article] Update of the Spanish Consensus Document on Infantile Hemangioma

    by E. Baselga, J. Bernabeu-Wittel, I. Betlloch Mas, M. Campos Domínguez, A. Carrasco Sanz, J. del Boz, R. de Lucas Laguna, J. del Pozo Losada, A. Hernández Martín, L. Jiménez Montañés, et al.

  • Open Access

    Non-Involuting Congenital Hepatic Hemangioma: Natural History and Management

    by Karla Estefania-Fernandez, Paloma Triana, Carla Ramirez‐Amoros, Mireia Gaspar-Perez, Antonio Jesús Muñoz-Serrano, Maria Velayos, Maria San Basilio, Nelson M. Buitrago Sánchez, Manuel Parron, Ane Andres, et al.

    Background: Focal liver hemangiomas have traditionally been considered as rapidly involuting tumors, akin to their cutaneous counterparts (RICH). However, non-involuting tumors remain poorly investigated and inadequately understood. This study explores the evolution patterns and management strategies for non-involuting congenital hepatic hemangiomas (NICHH). Methods: We conducted a retrospective review of clinical, imaging, histological, and genetic data of children diagnosed with NICHH (defined as having no signs of involution for at least 18 months) from 1991 to 2022. Results: We included 7 patients (5 females and 2 males) diagnosed with NICHH. The median age at diagnosis was 42 days (range: 0-1440). Seventy-one percent of lesions were asymptomatic, with the right hepatic lobe being the most common location (71.4%). Histological analysis was available in 3 patients confirming the diagnosis of CHH. A genetic study conducted in one patient identified a mutation in GNAQ gene. The median follow-up duration was of 75 months (range: 35-191). During follow-up, 3 patients with giant NICHH received sirolimus treatment, resulting in a partial response in 2 patients, while the lesion in the other patient remained stable. The 4 untreated patients exhibited various evolutionary patterns, some of which had not been previously described. Conclusions: This is the first case series to examine the long -term evolution of NICHH. Accurate diagnosis and periodic follow-up of these lesions can prevent unnecessary aggressive treatments. Sirolimus may offer a promising option for reducing the size or accelerate the involution of NICHH.

  • Open Access

    Actualización del documento de consenso español sobre el hemangioma infantil

    by E. Baselga, J. Bernabeu-Wittel, I. Betlloch Mas, M. Campos Domínguez, A. Carrasco Sanz, J. del Boz, R. de Lucas Laguna, J. del Pozo Losada, A. Hernández Martín, L. Jiménez Montañés, et al.


  • Open Access

    Sedoanalgesia in the Debridement of Pediatric Burns in the Emergency Department: Is It Effective and Safe?

    by Carlos Delgado-Miguel, Miriam Miguel-Ferrero, Andrea Ezquerra, Mercedes Díaz, María De Ceano-Vivas, Juan Carlos López-Gutiérrez

    Background: The routine use of sedoanalgesia has increased the number of potential minor surgical procedures that can be performed in the Emergency Department (ED) without requiring general anesthesia and, thus, hospital admission. Our aim is to analyze the effectiveness and safety of the use of sedoanalgesia in childhood burns treated in the ED. Methods: A retrospective study was conducted in burned children in whom burn debridement was performed under sedoanalgesia in the ED between 2017 and 2021 in a tertiary referral center for burns. We collected demographic variables, burn features and the type of sedoanalgesia performed in each case, including its effectiveness and associated adverse effects. Results: A total of 227 patients (118 males, 109 females) were included, with a median age of 25 months. In total, 99.2% of the burns were thermal (69.2% scald burns), with a mean total body surface area (TBSA) burned of 4%. The most commonly used drugs were intravenous ketamine (35.7%), intravenous ketamine + midazolam (15.4%), intranasal fentanyl + midazolam (14.1%) and intranasal fentanyl (10.6%). The effectiveness of sedoanalgesia was considered satisfactory in 95.2% of the cases, with an adverse effect rate of 7.5%, without severe adverse effects reported. Conclusions: The use of sedoanalgesia in the ED in the early treatment of childhood burns achieves high effectiveness and safety. It is postulated as a quality indicator; thus, it should be known by all pediatric healthcare practitioners.


  • Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series

    by María Dolores Corral Sánchez, Raquel Jiménez Carrascoso, Pedro Rubio Aparicio, Diego Plaza López de Sabando, Ana Sastre Urgelles, José Juan Pozo-Kreilinger, Juan Carlos López Gutiérrez, Manuel Gómez Cervantes, Eduardo José Ortiz Cruz, Antonio Pérez-Martínez

    Background Infantile fibrosarcoma is the most frequent soft tissue sarcoma in newborns or children under one year of age. This tumour often implies high local aggressiveness and surgical morbidity. The large majority of these patients carry the ETV6–NTRK3 oncogenic fusion. Hence, the TRK inhibitor larotrectinib emerged as an efficacious and safe alternative to chemotherapy for NTRK fusion-positive and metastatic or unresectable tumours. However, real-world evidence is still required for updating soft-tissue sarcoma practice guidelines. Objective To report our experience with the use of larotrectinib in pediatric patients. Methods Our case series shows the clinical evolution of 8 patients with infantile fibrosarcoma under different treatments. All patients enrolled in this study received informed consent for any treatment. Results Three patients received larotrectinib in first line. No surgery was needed with larotrectinib, which led to the rapid and safe remission of tumours, even in unusual anatomical locations. No significant adverse effects were observed with larotrectinib. Conclusion Our case series supports that larotrectinib may be a therapeutic option for newborn and infant patients with infantile fibrosarcoma, especially in uncommon locations.


  • Open Access

    Successful Sirolimus Treatment for Recurrent Pericardial Effusion in a Large Cervicomediastinal Provisionally Unclassified Vascular Anomaly: A Case Report

    by Julio César Moreno-Alfonso, María San Basilio Berenguer, María del Carmen Sarmiento Caldas, Jesús González Cayón, Santiago de la Puente, Paloma Triana, Juan Carlos López-Gutiérrez

    Provisionally unclassified vascular anomalies (PUVA) are a group of diseases with unique characteristics that make them unclassifiable within vascular tumors or malformations. We describe a PUVA as the cause of recurrent pericardial effusion and its response to sirolimus. A 6-year-old girl was referred with a cervicothoracic vascular anomaly, a violaceous, and irregular lesion in the neck and upper chest, diagnosed as “hemangioma”. She had pericardial effusion at the neonatal age that required pericardiocentesis, propranolol, and corticosteroids. She remained stable for 5 years, when she presented with a severe pericardial effusion. A magnetic resonance visualized a diffuse vascular image in the cervical and thoracic region with mediastinal extension. The pathological study showed a vascular proliferation in the dermis and hypodermis with positive staining for Wilms' Tumor 1 Protein (WT1) and negative for Glut-1. Genetic testing found a variant in GNA14, for which the diagnosis of PUVA was established. When a pericardial drain was placed without response, treatment with sirolimus was started with resolution of the effusion. Sixteen months later, the malformation is stable and there has been no recurrence of pericardial effusion. In a significant group of patients, definitive diagnosis is not possible despite pathological and genetic analysis. Mammalian target of rapamycin inhibitors may become a therapeutic option if symptoms are severe enough, with a low rate of reported side effects.